Children's Oncology Group's 2023 blueprint for research: Bone tumors

• Published in: Pediatric blood & cancer Vol. 70; no. S6; pp. e30583 - n/a
• Main Authors: Reed, Damon R., Grohar, Patrick, Rubin, Elyssa, Binitie, Odion, Krailo, Mark, Davis, Jessica, DuBois, Steven G., Janeway, Katherine A.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2023
• Subjects: Bone cancer; Bone Neoplasms - drug therapy; Bone Neoplasms - genetics; Bone sarcoma; Bone tumors; Chemotherapy; Child; Clinical trials; Ewing sarcoma; Ewing's sarcoma; Ewings sarcoma; Hematology; Humans; Metastases; Metastasis; Myc protein; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Oncology; Osteosarcoma; Osteosarcoma - drug therapy; Osteosarcoma - genetics; Pediatrics; research priorities; Sarcoma, Ewing - drug therapy; Sarcoma, Ewing - genetics; Bone sarcoma; Ewing sarcoma; research priorities; osteosarcoma
• ISSN: 1545-5009; 1545-5017; 1545-5017
• DOI: 10.1002/pbc.30583

The Children's Oncology Group (COG) Bone Tumor Committee is responsible for clinical trials and biological research on localized, metastatic, and recurrent osteosarcoma and Ewing sarcoma (EWS). Results of clinical trials in localized disease completed and published in the past 10 years have led to international standard‐of‐care chemotherapy for osteosarcoma and EWS. A recent focus on identifying disease subgroups has led to the identification of biological features associated with poor outcomes including the presence of circulating tumor DNA (ctDNA) at diagnosis, and specific genomic alterations—MYC amplification for osteosarcoma and STAG2 and TP53 mutation for EWS. Studies validating these potential biomarkers are under way. Clinical trials evaluating the addition of multitargeted kinase inhibitors, which are active in relapsed bone sarcomas, to standard chemotherapy are under way in osteosarcoma and planned in EWS. In addition, the Committee has data analyses and a clinical trial under way to evaluate approaches to local management of the primary tumor and metastatic sites. Given the rarity of bone sarcomas, we have prioritized international interactions and are in the process of forming an international data‐sharing consortium to facilitate refinement of risk stratification and study of rare disease subtypes.